EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

N V Pervushin, D K Nilov, S V Pushkarev, V O Shipunova, A S Badlaeva, M A Yapryntseva, D V Kopytova, B Zhivotovsky, G S Kopeina

Apoptosis · 2024-12 · 29 (11-12) · 2197-2213

DOI: 10.1007/s10495-024-02014-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, online erschienen am 02.09.2024. Verfasst von N V Pervushin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Russian Science Foundation, Cancerfonden, Cancerföreningen i Stockholm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of drug resistance reduces the efficacy of cancer therapy. Tumor cells can acquire resistance to MDM2 inhibitors, which are currently under clinical evaluation. We generated RG7388-resistant neuroblastoma cells, which became more proliferative and metabolically active and were less sensitive to DNA-damaging agents in vitro and in vivo, compared with wild-type cells. The resistance was associated with a mutation of the p53 protein (His193Arg). This mutation abated its transcriptional activity via destabilization of the tetrameric p53-DNA complex and was observed in many cancer types. Finally, we found that Cisplatin and various BH3-mimetics could enhance RG7388-mediated apoptosis in RG7388-resistant neuroblastoma cells, thereby partially overcoming resistance to MDM2 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Drug Resistance, NeoplasmMutationApoptosisHumansCell Line, TumorAnimalsMiceDNA DamageNeuroblastomaCisplatinAntineoplastic AgentsPyrrolidinespara-Aminobenzoates

Stichwörter der Autor:innen

BH3-mimeticsDrug resistanceMDM2RG7388p53 mutation

Substanzen

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53RG7388CisplatinMDM2 protein, humanAntineoplastic AgentsPyrrolidinespara-Aminobenzoates

Autor:innen und Institutionen

  • Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
  • Faculty of Medicine, MV Lomonosov Moscow State University, Moscow, 119991, Russia.
  • Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Moscow, 119991, Russia.
  • Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, 119234, Russia.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russia.
  • Moscow Center for Advanced Studies, Moscow, 123592, Russia.

Förderung

  • The Russian Science Foundation
  • Cancerfonden
  • Cancerföreningen i Stockholm
  • Karolinska Institute

Zitieren

APA

Pervushin, N. V., Nilov, D. K., Pushkarev, S. V., Shipunova, V. O., Badlaeva, A. S., Yapryntseva, M. A., Kopytova, D. V., Zhivotovsky, B., & Kopeina, G. S. (2024). BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis, 29(11-12), 2197-2213. https://doi.org/10.1007/s10495-024-02014-8

Vancouver

Pervushin NV, Nilov DK, Pushkarev SV, Shipunova VO, Badlaeva AS, Yapryntseva MA, et al. BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition. Apoptosis. 2024;29(11-12):2197-2213. doi:10.1007/s10495-024-02014-8

BibTeX
@article{Pervushin2024,
  author = {Pervushin, N V and Nilov, D K and Pushkarev, S V and Shipunova, V O and Badlaeva, A S and Yapryntseva, M A and Kopytova, D V and Zhivotovsky, B and Kopeina, G S},
  title = {BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition},
  journal = {Apoptosis},
  year = {2024},
  volume = {29},
  number = {11-12},
  pages = {2197--2213},
  doi = {10.1007/s10495-024-02014-8}
}
Kostenlos starten →